- Home
- OLMA vs ADCT Comparison
OLMA vs ADCT Comparison
Compare OLMA & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- ADCT
- Stock Information
- Founded
- OLMA 2006
- ADCT 2011
- Country
- OLMA United States
- ADCT Switzerland
- Employees
- OLMA N/A
- ADCT N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- OLMA Health Care
- ADCT Health Care
- Exchange
- OLMA Nasdaq
- ADCT Nasdaq
- Market Cap
- OLMA 299.7M
- ADCT 241.0M
- IPO Year
- OLMA 2020
- ADCT 2020
- Fundamental
- Price
- OLMA $4.20
- ADCT $2.78
- Analyst Decision
- OLMA Strong Buy
- ADCT Strong Buy
- Analyst Count
- OLMA 4
- ADCT 6
- Target Price
- OLMA $24.50
- ADCT $7.80
- AVG Volume (30 Days)
- OLMA 868.7K
- ADCT 937.9K
- Earning Date
- OLMA 08-05-2025
- ADCT 08-05-2025
- Dividend Yield
- OLMA N/A
- ADCT N/A
- EPS Growth
- OLMA N/A
- ADCT N/A
- EPS
- OLMA N/A
- ADCT N/A
- Revenue
- OLMA N/A
- ADCT $75,817,000.00
- Revenue This Year
- OLMA N/A
- ADCT $10.65
- Revenue Next Year
- OLMA N/A
- ADCT $15.05
- P/E Ratio
- OLMA N/A
- ADCT N/A
- Revenue Growth
- OLMA N/A
- ADCT 10.49
- 52 Week Low
- OLMA $2.86
- ADCT $1.05
- 52 Week High
- OLMA $16.62
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- OLMA 43.60
- ADCT 47.62
- Support Level
- OLMA $3.90
- ADCT $3.21
- Resistance Level
- OLMA $4.29
- ADCT $3.97
- Average True Range (ATR)
- OLMA 0.36
- ADCT 0.38
- MACD
- OLMA -0.03
- ADCT -0.12
- Stochastic Oscillator
- OLMA 19.18
- ADCT 3.43
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).